Unexplained Leukocytosis in an Adult

Eileen Scigliano, MD

Mount Sinai School of Medicine, New York, NY

Copyright of the American Society of Hematology, 2006. ISSN: 1931-6860.

This case was reviewed and updated in March 2013 by Dr. Marc J. Kahn and members of the Teaching Cases Subcommittee.

VIII. BIBLIOGRAPHY

Cortes J, Kantarjian H, Shah N, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias . N Engl J Med. 2012; 367(22):2075-88.

Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.

Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110:2828-2837.

Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349:1423-1432.

Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008; 111:1774-1780.

Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619-1630.

Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining (editorial). Nature. 1973; 243:290-293.

Have a question or comment about the ASH Teaching Cases? Please e-mail webmaster@hematology.org.